ArmitageP.Statistical methods in medical research. Oxford: Blackwell, 1971.
2.
Bioequivalence Task Force report. Rockville, MD: Food and Drug Administration, February, 1988.
3.
SchuirmannDJ. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm1987; 15: 657–80.
4.
FishLHSchwartzHLCovanaughJ.SteffesMWBantleJROppenheimerJH. Replacement dose, metabolism and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med1987; 316: 764–70.
5.
SawinCTSusksMILondonM.RnaganathanC.LarsenPR. Oral thyroxine: Variation in biological action and tablet content. Ann Intern Med1984; 100: 641–5.
6.
Levothyroxine and levothyroxine tablets monographs. United States pharmacopeia XIX (1975); X (1980); and XXI (1985). Rockville, MD: U.S. Pharmacopeial Convention, Inc.
7.
Rees-JonesRWLarsenPR. Triiodothyronine and thyroxine content of desiccated thyroid tablets. Metabolism1977; 126: 1213–8.
8.
Rees-JonesRWRolaARLarsenPR. Hormonal content of thyroid replacement preparations. JAMA1980; 243: 549–50.
9.
LarsenPR. Direct immunoassay of triiodothyronine in human serum. J Clin Invest1972; 51: 1939–49.
10.
LarsenPRDockaloraJ.SipulaD.WufM.Immunoassay of thyroxine in unextracted human serum. J Clin Endocrinol Metab1973; 37: 177–82.
11.
LarsenPR. The present compendial condition of thyroid hormones and thyroid hormone preparations. In: Hormone drugs: Proceedings of the FDA-USP workshop on drug and reference standards for insulins, somatotropins and thyroid axis hormones. Bethesda, MD, May 19–21, 1982. Rockville, MD: U.S. Pharmacopeial Convention, Inc., 1982.
